On August 24, Keya Medical’s flagship product, DeepVessel FFR, was successfully implemented in Beijing Anzhen Hospital.
Artificial intelligence and other advanced informatics could be applied to coronary CTA images to unlock valuable information on atherosclerotic plaque characteristics that could be used to personalize care decisions. Learn more.
Learn more about the encouraging recent developments in the use of targeted fee-for-service models as a transition strategy to ensure that patients have access to proven advanced diagnostics and treatments.
Examine the current challenges for coronary CTA reimbursement, the potential effects it will have on patient care, and what medical imagers can do to help improve reimbursement moving forward.
Keya Medical showcased its deep learning-based diagnostic and treatment solutions at the World Artificial Intelligence Conference 2021 (WAIC 2021) held in Shanghai.